Enochian Biosciences, Inc.
ENOB
Price:
$0.7125
Market Cap:
$94.09M
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, In...[Read more]
Industry
Biotechnology
IPO Date
2018-02-07
Stock Exchange
NASDAQ
Ticker
ENOB
The ROE as of September 2024 (TTM) for Enochian Biosciences, Inc. (ENOB) is -70.62%
According to Enochian Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -70.62%. This represents a change of 213.87% compared to the average of -22.50% of the last 4 quarters.
Enochian Biosciences, Inc. (ENOB) Historical ROE (quarterly & annually)
How has ENOB ROE performed in the past?
The mean historical ROE of Enochian Biosciences, Inc. over the last ten years is -18.21%. The current -70.62% ROE has changed 287.88% with respect to the historical average. Over the past ten years (40 quarters), ENOB's ROE was at its highest in in the March 2022 quarter at -3.85%. The ROE was at its lowest in in the June 2022 quarter at -124.26%.
Average
-18.21%
Median
-12.85%
Minimum
-156.20%
Maximum
272.24%
Enochian Biosciences, Inc. (ENOB) ROE by Quarter and Year
Discovering the peaks and valleys of Enochian Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 920.93%
Maximum Annual ROE = 272.24%
Minimum Annual Increase = -151.35%
Minimum Annual ROE = -156.20%
| Year | ROE | Change |
|---|---|---|
| 2023 | -85.34% | -45.37% |
| 2022 | -156.20% | 920.93% |
| 2021 | -15.30% | 122.84% |
| 2020 | -6.87% | -34.03% |
| 2019 | -10.41% | 161.76% |
| 2018 | -3.98% | -97.16% |
| 2017 | -139.80% | -151.35% |
Enochian Biosciences, Inc. (ENOB) Average ROE
How has ENOB ROE performed in the past?
The current ROE of Enochian Biosciences, Inc. (ENOB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-85.61%
5-year avg
-54.82%
10-year avg
-18.21%
Enochian Biosciences, Inc. (ENOB) ROE vs. Peers
How is ENOB’s ROE compared to its peers?
Enochian Biosciences, Inc.’s ROE is greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Adagene Inc. (-63.48%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than Rezolute, Inc. (-60.90%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than MediciNova, Inc. (-13.37%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Eliem Therapeutics, Inc. (-47.03%),
| Company | ROE | Market cap |
|---|---|---|
| -83.65% | $55.14M | |
| -63.48% | $121.74M | |
| -47.31% | $254.90M | |
| -60.90% | $285.09M | |
| -54.72% | $31.33M | |
| -33.08% | $172.94M | |
| -42.61% | $576.83M | |
| -36.89% | $1.11B | |
| -62.74% | $297.22M | |
| -122.97% | $54.20M | |
| -21.96% | $77.28M | |
| -13.37% | $88.28M | |
| 323.52% | $67.97M | |
| -23.13% | $108.71M | |
| -47.03% | $552.58M |
Build a custom stock screener for Enochian Biosciences, Inc. (ENOB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enochian Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Enochian Biosciences, Inc. (ENOB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Enochian Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Enochian Biosciences, Inc.'s ROE?
How is the ROE calculated for Enochian Biosciences, Inc. (ENOB)?
What is the highest ROE for Enochian Biosciences, Inc. (ENOB)?
What is the 3-year average ROE for Enochian Biosciences, Inc. (ENOB)?
What is the 5-year average ROE for Enochian Biosciences, Inc. (ENOB)?
How does the current ROE for Enochian Biosciences, Inc. (ENOB) compare to its historical average?